Advertisement

Biofilms and Ventilation

Chapter
Part of the Springer Series on Biofilms book series (BIOFILMS, volume 3)

Abstract

The need for mechanical ventilation (MV) has paralleled the growth of the ICU for a ageing population with multiple disease entities, particularly those associated with pulmonary diseases. As the process of ventilation has improved, the etiology of Ventilator-Associated Pneumonia (VAP) has moved from the instrumentation to the colonization of the patient, focusing most recently on the link of normal oral flora as the initial, catalyzing insult in patients at risk for pneumonia through a biofilm in the lumen of the endotrachial tube (ETT).

The ETT, particularly the lumen, is an unrecognised reservoir for biofilms in the evolving discussion of indwelling medical device (IMD)-associated infections; yet it is the perfect environment for such communities to form. The endotrach lumen is protected from systemic therapeutic interventions. The environment is rich with the parameters associated with biofilm development.

Risk factors for ventilator-associated pneumonia and development of ETT luminal biofilms are multi-factorial including: length of hospitalization, surgery, prior antibiotic usage, stress ulcer prophylaxis, host factors such as ARDS, upper aspiratory colonization, and poor oral hygiene. The most significant risk factors, however, appear to be length of mechanical ventilation and prior exposure to antibiotic therapy.

Keywords

Quorum Sensing Respir Crit Multiple Organ Dysfunction Syndrome Nosocomial Pneumonia Infectious Disease Society 
These keywords were added by machine and not by the authors. This process is experimental and the keywords may be updated as the learning algorithm improves.

Preview

Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.

References

  1. American Thoracic Society; Infectious Diseases Society of America (2005) Guidelines for the management of adults with hospital-acquired, ventilator-associated, and healthcare-associated pneumonia. Am J Respir Crit Care Med 171:388–416CrossRefGoogle Scholar
  2. Balaban N, Stoodley P, Fux CA, Wilson S, costerton JW, Dell’Acqua G (2005) Prevention of staphylococcal biofilm-associated infections by quorum sensing inhibitor RIP. Clin Orthop Relat Res 437:48–54PubMedCrossRefGoogle Scholar
  3. Bauer TT, Torres A, Ferrer R, Heyer CM, Schultze-Werninghaus G, Rasche K (2002) Biofilm formation in endotracheal tubes: association between pneumonia and the persistence of pathogens. Monaldi Arch Chest Dis 57:84–87PubMedGoogle Scholar
  4. Beck-Schimmer B, Madjdpour C, Kneller S, Ziegler U, Pasch T, Wuthrich RP, Ward PA, Schimmer RC (2002) Role of alveolar epithelial ICAM-1 in lipopolysaccharide-induced lung inflammation. Eur Respir J 19:1142–1150PubMedCrossRefGoogle Scholar
  5. Beck-Schimmer B, Schimmer RC, Pasch T (2004) The airway compartment: chambers of secrets. News Physiol Sci 19:129–132PubMedGoogle Scholar
  6. Bonten MJ, Kollef MH, Hall JB (2004) Risk factors for ventilator-associated pneumonia: from epidemiology to patient management. Clin Infect Dis 38:1141–1149PubMedCrossRefGoogle Scholar
  7. Cason CL, Tyner T, Saunders S, Broome L (2007) Nurses’ implementation of guidelines for ventilator-associated pneumonia from the Centers for Disease Control and Prevention. Am J Crit Care 16:28–38PubMedGoogle Scholar
  8. Charles PE, Martin L, Etienne M, Croisier D, Piroth L, Lequeu C, Pugin J, Portier H, Chavanet P (2004) Influence of positive end-expiratory pressure (PEEP) on histopathological and bactreriological aspects of pneumonia during low tidal volume mechanical ventilation. Intensive Care Med 30:2263–2270PubMedCrossRefGoogle Scholar
  9. Chastre J, Fagon YT (2002) Ventilator-associated pneumonia. Am J Respir Crit Care Med 165:867–903PubMedGoogle Scholar
  10. Clutterbrick A et al. (2007) Evaluating antibiotics for use in medicine using a poloxamer biofilm model. Ann. Clin. Micro. and Antimicrobials 6(2)Google Scholar
  11. Cook DJ, Walter SD, Cook RJ (1998) Incidence of and risk factors for ventilator-associated pneumonia in critically ill patients. Ann Intern Med 129:433–440PubMedGoogle Scholar
  12. Davis KA (2006) Ventilator-associated pneumonia: a review. J Intensive Care Med 21:211–226PubMedCrossRefGoogle Scholar
  13. DeRiso AJ II, Ladowski JS, Dillon TA, Justice JW, Peterson AC (1996) Chlorhexidine gluconate 0.12% oral rinse reduces the incidence of total nosocomial respiratory infection and non-prophylactic systemic antibiotic use in patients undergoing heart surgery. Chest 109:1556–1561PubMedCrossRefGoogle Scholar
  14. Dhanireddy S, Altemeier WA, Matute-Bello G, O’Mahony DS, Glenny RW, Martin TR, Liles WC (2006) Mechanical ventilation induces inflammation, lung injury, and extra-pulmonary organ dysfunction in experimental pneumonia. Lab Invest 86:790–799PubMedCrossRefGoogle Scholar
  15. Donlan RM, Costerton JW (2002) Biofilms: survival mechanisms of clinically relevant microorganisms. Clin Microbiol Rev 15:167–193PubMedCrossRefGoogle Scholar
  16. Dupont H, Mentec H, Sollet JP, Bleichner G (2001) Impact of appropriateness of initial antibiotic therapy on the outcome of ventilator-associated pneumonia. Intensive Care Med 27:355–362PubMedCrossRefGoogle Scholar
  17. Fagon JY, Rello J (2006) Targeted antibiotic management of ventilator-associated pneumonia. Clin Microbiol Infect 12(Suppl 9):S17–S22CrossRefGoogle Scholar
  18. Fourrier F, Cau-Pottier E, Boutigny H, Roussel-Delvallez M, Jourdain M, Chopin C (2000) Effects of dental plaque antiseptic decontamination on bacterial colonization and nosocomial infections in critically ill patients. Intensive Care Med 26:1239–1247PubMedCrossRefGoogle Scholar
  19. Fux CA, Costerton JW, Stewart PS, Stoodley P (2005) Survival strategies of infectious biofilms. Trends Microbiol 13:34–40PubMedCrossRefGoogle Scholar
  20. Gilbert P et al. (1998) The use of poloxamer hydrogels for the assessment of biofilm susceptibility towards biocide treatment. J Appl Micro 85:985–990Google Scholar
  21. Grap MJ, Munro CL, Elswick RK Jr, Sessler CN, Ward KR (2004) Duration of action of a single, early, oral application of chlorhexidine on oral microbial flora in mechanically ventilated patients: a pilot study. Heart Lung 33:83–91PubMedCrossRefGoogle Scholar
  22. Habish M, Reid G (1999) Microbial biofilms: their development and significance for medical device-related infections. J Clin Pharmacol 39:887–898CrossRefGoogle Scholar
  23. Hoffken G, Niederman MS (2002) Nosocomial pneumonia: the importance of a de-escalating strategy for antibiotic treatment of pneumonia in the ICU. Chest 122:2183–2196PubMedCrossRefGoogle Scholar
  24. Houston S, Hougland P, Anderson JJ, LaRocco M, Kennedy V, Gentry LO (2002) Effectiveness of 0.12% chlorhexidine gluconate oral rinse in reducing prevalence of nosocomial pneumonia in patients undergoing heart surgery. Am J Crit Care 11:567–570PubMedGoogle Scholar
  25. Ibrahim EH, Sherman G, Ward S, Fraser VJ, Kollef MH (2000) The influence of inadequate antimicrobial treatment of bloodstream infections on patient outcomes in the ICU setting. Chest 118(1):146–155PubMedCrossRefGoogle Scholar
  26. Imai Y, Parodo J, Kajikawa O, de Perrot M, Fischer S, Edwards V, Cutz E, Liu M, Deshavjee S, Martin TR, Marshall JC, Ranieri VM, Slutsky AS (2003) Injurious mechanical ventilation and end-rogan epithelial cell apoptosis and organ dysfunction in an experimental model of acute respiratory distress syndrome. JAMA 289:2104–2112PubMedCrossRefGoogle Scholar
  27. Inglis T, Lim TM, Ng ML, Tang EK, Hui KP (1995) Structural features of tracheal tube biofilm formed during prolonged mechanical ventilation. Chest 106:1049–1052CrossRefGoogle Scholar
  28. Isakow W, Kollef MH (2006) Preventing ventilator-associated pneumonia; an evidence-based approach of modifiable risk factors. Semin Respir Crit Care Med 27:5–17PubMedCrossRefGoogle Scholar
  29. Kollef M (2002) Ventilator-associated pneumonia and ventilator induced lung injury: two peas in a pod. Crit Care Med 30:2391–2392PubMedCrossRefGoogle Scholar
  30. Kollef MH (2005) What is ventilator-associated pneumonia and why is it important? Chest 50:714–721Google Scholar
  31. Kollef MH (2007) Moving towards real-time antimicrobial management of ventilator-associated pneumonia. Clin Infect Dis 44:388–390. Epub 2007 Jan 3PubMedCrossRefGoogle Scholar
  32. Kollef MH, Shorr A, Tabak YP, Gupta V, Liu LZ, Johannes RS (2005) Epidemiology and outcomes of healthcare-associated pneumonia: results from a large US database of culture-positive pneumonia. Chest 128:3854–3862PubMedCrossRefGoogle Scholar
  33. Linden PK, Paterson DL (2006) Parenteral and inhaled colistin for treatment of ventilator-associated pneumonia. Clin Infect Dis 43(Suppl 2):S89–S94PubMedCrossRefGoogle Scholar
  34. Leid JG, Wilson CJ, Shirtliff ME, Hassett DJ, Parsek MR, Jeffers AK (2005) The Exopolysaccharide alginate protects Pseudomonas aeruginosa biofilm bacteria from IFN-γ-mediated macrophage killing. J Immunol. 171:5886–5894Google Scholar
  35. Leone M, Garcin F, Bouvenot J, Boyadjev I, Visintini P, Albanese J, Martin C (2007) Ventilatorassociated pneumonia: breaking the vicious circle of antibiotic overuse. Crit Care Med 35(2):379–385PubMedCrossRefGoogle Scholar
  36. Madjdpour C, Oertli B, Ziegler U, Bonvini JM, Pasch T, Beck-Schimmer B (2000) Lipopolysaccharide induces functional ICAM-1 expression in rat alveolar epithelial cells in vitro. Am J Physiol Lung Cell Mol Physiol 278:L572–L579PubMedGoogle Scholar
  37. Madjdpour C, Jewell UR, Sneller S, Ziegler U, Schwendener R, Booy C, Klausli L, Pasch T, Schimmer RC, Beck-Schimmer B (2003) Decreased alveolar oxygen induces lung inflammation. Am J Physiol Lung Cell Mol Physiol 284:L360–L367PubMedGoogle Scholar
  38. Mandell LA, Wunderlink RG, Anzueto A, Bartlett JG, Campbell GD, Dean NG, Dowell SF, File TM Jr, Musher DM, Niederman MS, Torres A, Whitney CG (2007) Infectious disease society of America; American thoracic society guidelines for community-acquired Pneumonia in adults. Clin Infect Dis 44(Suppl 2):S27–S72PubMedCrossRefGoogle Scholar
  39. Pacheco-Fowler V, Gaonkar T, Wyer PC, Modak S (2004) Antiseptic impregnated endotracheal tubes for the prevention of bacterial colonization. J Hosp Infect 57:170–174PubMedCrossRefGoogle Scholar
  40. Rello J, Diaz E, Roque M, Valles J (1999) Risk factors for developing pneumonia within 48 hours of intubation. Am J Respir Crit Care Med 159:1742–1746PubMedGoogle Scholar
  41. Rello J, Ollendorf DA, Oster G, Vera-Llonch M, Bellm K, Redman R, Kollef MH (2002) Epidemiology and outcomes of ventilator-associated pneumonia in a large US database. Chest 122:2115–2121PubMedCrossRefGoogle Scholar
  42. Rello J, Kollef M, Diaz E, Sandiumenge A, delCastillo Y, Corbella X, Zachskom R (2006) Reduced burden of bacterial airway colonization with a novel silver-coated endotracheal tube in a randomized multiple-center feasibility study. Crit Care Med 34:2766–2772PubMedCrossRefGoogle Scholar
  43. Ruiz M, Torres A, Ewig S, Marcos MA, Alcon A, Lledo R, Asenjo MA, Maldonaldo A (2000) Noninvasive versus invasive microbial investigation in ventilator-associated pneumonia: evaluation of outcome. Am J Respir Crit Care Med 162:119–125PubMedGoogle Scholar
  44. Sanchez-Nieto JM, Torres A, Garcia-Cordoba F, El-Ebiary M, Carrillo A, Ruiz J, Nunez ML, Niederman M (1998) Impact of invasive and noninvasive quantitative culture sampling on outcome of ventilator-associated pneumonia: a pilot study. Am J Respir Crit Care Med 157:371–376. Erratum in Am J Respir Crit Care Med 1998;157:1005Google Scholar
  45. Slutsky AS, Ranieri VM (2000) Mechanical ventilation: lessons from the ARDSNet trial. Respir Res 1:73–77PubMedCrossRefGoogle Scholar
  46. Tablan OC, Anderson IJ, Besser R, Bridges C, Hajjeh R (2004) Guidelines for preventing healthcareassociated pneumonia, 2003: recommendations of DCD and the Healthcare Infection Control Practices Advisory Committee. MMWR Recomm Rep 53(RR-3):1–36PubMedGoogle Scholar
  47. Zee ED, Schomberh S, Carpenter TC (2006) Hypoxia upregulates lung microvascular neurokinin-1 receptor expression. Am J Physiol Lung Cell Mol Physiol 291:L102–L110PubMedCrossRefGoogle Scholar

Copyright information

© Springer-Verlag Berlin Heidelberg 2008

Authors and Affiliations

  1. 1.Department of PathologyWest Virginia University School of MedicineMorgantownUSA
  2. 2.Department of Pathology, ProteomicsWest Virginia UniversityMorgantownUSA
  3. 3.Clinical Services GroupPharm D, Health Corporation of AmericaNashvilleUSA

Personalised recommendations